Tumor necrosis factor type a (TNF-a) inhib-
Tumor necrosis factor type a (TNF-a) is a polypeptide originally identified in the serum of mice infected with bacillus Calmette-Guerin and then treated with endotoxin (1). This protein was later isolated from macrophages (2) and its structure was determined by cDNA cloning (3) . It is identical to cachectin (2) and structurally (4) and biologically (5) related to the lymphocyte product lymphotoxin (TNF-,B).
TNF-a causes hemorrhagic necrosis and complete regression of certain transplanted tumors in mice (1) , induces wasting (cachexia) and a lethal state of shock (6) , and inhibits metastasis formation in animals (7) . A variety of in vitro effects have been reported: TNF-a is cytostatic or cytolytic for several human or murine carcinoma, melanoma, and sarcoma cell lines and also for virally transformed 3T3 cells (8, 9) . However, TNF-a is not cytotoxic or growth inhibitory for various normal cells (1, 6) . It can even stimulate the proliferation of some cell types (9, 10) . Furthermore, TNF-a suppresses lipoprotein lipase activity in adipocytes (11) and collagen and proteoglycan synthesis in osteoclasts (12) and cartilage (13) , respectively. It has been shown to stimulate the formation of prostaglandin E2 (14, 15) , collagenase (15) , interleukin 1 (14, 16) , interferons (17, 18) , and granulocyte/ macrophage colony-stimulating factor (GM-CSF) (19) in fibroblasts, macrophages, or synovial cells. TNF-a is also antiviral for a number of cell types (20, 21) . Finally, TNF-a exhibits a variety of activities toward endothelial cells, including the stimulation of procoagulant activity (22, 23) , GM-CSF (19, 24) , interleukin 1 (16) , cell-surface antigen expression (25, 26) and the inhibition of proteoglycan synthesis (13) and cell growth (18, 27) . Those observations suggest that the vascular endothelial system may be a target for TNF-a action in vivo.
The mechanism for TNF-a-induced tumor necrosis and regression is unknown. Recently observed inhibitory effects of TNF-a on endothelial cells raise the question whether TNF could affect tumor necrosis/regression, at least partially, through inhibition of endothelial cell proliferation in vivo-i.e., inhibition of tumor neovascularization. To investigate this hypothesis we studied the effect of TNF-a on endothelial cell proliferation in vitro and on angiogenesis in vivo. We report that TNF-a is a potent noncytotoxic growth inhibitor for endothelial cells in culture but enhances rather than blocks neovascularization.
MATERIALS AND METHODS
Recombinant human TNF-a (produced in Escherichia coli) was provided by Knoll GmbH (Ludwigshafen, Federal Republic of Germany). The purity of TNF-a was >99%, its specific activity (7.4 x 106 units/mg of protein) was tested in an L 929 cytotoxicity assay (without actinomycin D), the endotoxin level was 0.07 ng/mg of protein, and residual bacterial proteins were 50 ng/mg of protein. Basic and acidic fibroblast growth factors (bFGF and aFGF) were isolated from bovine pituitary and brain, respectively, as described (28, 29) .
Cell Culture. Bovine aortic arch endothelial cells were prepared and cultured (passages 2-11) in Dulbecco's modified Eagle's medium (DMEM) with 10% calf serum (Hyclone, Logan, UT) in the presence of bFGF or aFGF as described (28) (29) (30) . Bovine brain capillary endothelial cells were provided by D. Gospodarowicz (University of California, San Francisco) and cultured as described for aortic endothelial cells. Bovine smooth muscle cells were prepared from the aortic arch as described (31) and grown in the medium used for endothelial cells. Endothelial cells were identified by using fluorescently labeled acetylated low density lipoprotein (32) and smooth muscle cells were identified by their typical hill-and-valley morphology at confluence (31) .
Growth-Inhibition Assay in Vitro. Cells were seeded in 35-mm plastic dishes (Falcon) at densities of 10,000-100,000 cells per dish, depending on cell type, and grown for [5] [6] [7] (36) containing 50-500 ng of bFGF and/or 0.5-50 ug of TNF-a and a constant amount of rabbit serum albumin (to achieve 20% loading of the polymer) were prepared and implanted in the rabbit cornea and the response was evaluated as described (36, 37) . RESULTS TNF-a inhibits the basal proliferation of bovine aortic and capillary endothelial cells cultured in serum-containing medium ( Fig. 1) . Inhibition was dose-dependent from 0.1 to 10 ng of TNF-a per ml with 50% inhibition occurring at -1 ng/ml (Fig. 1 ). The proliferation of those cells was also inhibited at similar TNF-a doses, when cell growth was stimulated by the addition of bFGF or aFGF (Fig. 2 Furthermore, TNF-a inhibited smooth muscle cell growth in the same dose range (Fig. 1) .
TNF-a acts as a noncompetitive antagonist of FGFstimulated endothelial cell growth. This conclusion is based on the observation that bFGF stimulated cell growth in an identical dose-dependent fashion (with very similar halfmaximal stimulatory concentrations), regardless of whether TNF-a was added (Fig. 3) . Furthermore, supramaximal doses of bFGF (e.g., 10 ng/ml, a 10-fold excess over the saturating concentration) were ineffective in overcoming the TNF-induced antiproliferative effect on cell growth.
Two experimental approaches did not show TNF-a cytotoxicity for bovine endothelial cells. In the long-term cytotoxicity assay ( Values are means ± SD of triplicates.
consistently but only slightly (20-30%) lower in TNF-atreated than in control cultures, regardless of the TNF-a dose. The apparently lower number of attached cells after TNF-a treatment is likely not to be due to a cytotoxic effect, because confluent endothelial cells continue to proliferate at a low rate (data not shown), whereas in TNF-a-treated cells this residual proliferation is suppressed. In a short-term cytotoxicity assay, TNF-a did not cause an increased leakage of "1'In from prelabeled aortic endothelial cells (Table 2) .
Furthermore, TNF-a toxicity on actively growing endothelial cells was evaluated by counting cells in culture supernatants. Very few suspended cells were observed under such conditions regardless of TNF doses (up to 140 ng/ml) and incubation times (up to 5 days). TNF-a-induced inhibition of endothelial cell proliferation is reversible. Upon removal of TNF-a from cells incubated for 5 days with the inhibitor (1.4 ng/ml), cell growth in response to bFGF or serum was normal again (data not shown).
To test possible activity of TNF-a in vivo, we assessed its action on angiogenesis in the rabbit cornea. Since bFGF is a well-known angiogenesis factor in this animal model, the actions of TNF-a and bFGF were compared, and particularly it was tested if TNF-a inhibited FGF-induced neovascularization. Rabbit cornea angiogenesis induced by 0.5 pug of bFGF is shown in Fig. 4d . Unexpectedly, 0.5, 5, and 10 ,ug doses of TNF-a also caused an angiogenic response (see Fig.  4c for the 5 ,g dose), with 0.5 ,g representing a minimally active dose. The angiogenic response of 5 ,ug of TNF-a was comparable to that of 0.5 ,ug of bFGF. Despite the fact that TNF-a is an inhibitor of FGF-induced endothelial cell growth in vitro, it does not prevent the angiogenic response caused by bFGF. This was established by evaluating the effects of 0.1, 0.5, 5, and 10 ,g of TNF-a in the presence of 0.5 ,ug of bFGF. Typical responses are shown in Fig. 4 a and b. The above described experiments were repeated with quantitatively identical results. TNF-a at concentrations of 5 ,ug or above evoked an inflammatory response, as evidenced by a cloudy cornea and a massive invasion of blood vessels from the limbus (Fig. 4b) and by histologic examination of eponembedded corneas, which showed a large number of infiltrating leukocytes (data not shown). Furthermore, TNF-ainduced angiogenesis was associated with leaky blood vessels, as evidenced by minor hemorrhage surrounding the tips of newly formed capillaries. The inflammatory response to TNF-a occurred regardless of whether TNF-a was implanted (8, 9) . The data presented here show that TNF-a is also a potent inhibitor of the in vitro growth of two types of vascular endothelial cells, confirming in part the results of other recent reports (18, 27) . TNF-a inhibits with similar potency the growth of endothelial cells promoted by serum alone and the additional growth observed with growth factor-supplemented serum (aFGF and bFGF). This activity of TNF-a is not restricted to endothelial cells; arterial smooth muscle cell growth is also inhibited. However, the proliferation of several other normal cells is not inhibited by TNF-a (9, 10) . Previous evidence obtained with tumor cell lines (8) but also with endothelial cells (18, 27, 38) suggests that the inhibitory activity of TNF-a may be largely due to cytotoxicity of this protein for those cell types. (18, 27) . The reasons for those discrepancies are unclear. It remains to be determined whether small experimental differences such as different culture conditions, differences in the origins of cells (human umbilical versus bovine aortic), or inhibitor (purified natural versus recombinant TNF-a) play a role.
Our data suggest that the inhibition of FGF-stimulated growth of endothelial cells is not mediated by a competition of TNF-a for the FGF receptor. Otherwise, very little is known with respect to the cellular mechanism of TNF-a inhibitory action on endothelial cells. Recently it was shown (17) that in fibroblasts TNF-a induces the expression of interferon-/32 mRNA and protein, which presumably modulates cell growth. Since interferons have already been demonstrated to be inhibitory for endothelial cell growth (18, 39, 40) , it will be of interest to establish whether a similar mechanism also works in those cells. Obviously, other mechanisms need to be considered as well, such as, for example, modulation of the expression of growth factor receptors and receptor down-regulation by TNF-a.
It should be noted that activities of TNF-a on endothelial cells described here resemble qualitatively those of another regulatory protein, transforming growth factor type /8 (TGF-,8), which is also a highly potent, reversible, and noncytotoxic inhibitor of basal or stimulated endothelial cell growth (41) (42) (43) , It is interesting that TNF-a and TGF-pB are both bifunctional with respect to their activities on cell proliferation. Depending on cell types and culture conditions they can act either as growth stimulators or inhibitors (9, 44) . TNF-a and TGF-/3, as well as interferons, which are also inhibitory for endothelial cells (39) , are well-established regulatory proteins, the physiological significance of which was originally thought to be associated with initially recognized biological activities-i.e., necrotic/cytotoxic, transforming, and antiviral activity, respectively. Recently it has become increasingly clear, however, that those factors are also antimitogenic for a variety of cell types (45 Cell Biology: Fra'ter-Schr6der et al. and interferons may possess as yet unrecognized physiological properties. It is conceivable, for example, that they fulfill a negative local regulatory role in the control of cell proliferation by counteracting the mitogenic activities of tissue growth factors-e.g., the omnipresent bFGF. TGF-/3 occurs rather ubiquitously in tissues. Interferon production can be induced in most cells and TNF-a is brought into tissues by means of activated macrophages. All three factors seem therefore strategically placed to act as local growth inhibitors.
We have explored this hypothesis by investigating whether TNF-a inhibits endothelial cell proliferation in vivo and, hence, neovascularization. An additional argument for those studies was the possibility that TNF-a-induced tumor necrosis may be, at least in part, a result of the inhibition of tumor neovascularization. In this context the observation of a stimulatory effect of TNF-a on angiogenesis in the rabbit cornea was surprising. The present data demonstrate that TNF-a causes the ingrowth of capillary blood vessels into the cornea and appears to enhance rather than inhibit bFGFinduced angiogenesis in the same in vivo model.
It is important to distinguish between TNF-a and the well-established angiogenesis factors such as bFGF (46) . Although the latter induce capillary vessel formation in the absence of an inflammatory reaction, angiogenesis caused by TNF-a is accompanied by inflammation. Furthermore, TNFa, especially at higher doses, causes newly formed blood vessels to leak, which is noticeable as a weak hemorrhage. It is well known that inflammation-i.e., the infiltration of macrophages into the inflammatory site-represents by itself an angiogenic stimulus. Presumably, macrophages can produce and release angiogenic factors such as bFGF (47) and possibly others of unknown nature. Alternative mechanisms, such as TNF-a-induced local production of angiogenic factors (e.g., prostaglandin E2), should be investigated as well.
Finally, it is interesting to note that the resemblance between TNF-a and TGF-P in vitro extends to neovascularization in vivo. Like TNF-a, TGF-f3 stimulates angiogenesis (48) . Moreover, with both proteins angiogenesis is associated with an inflammatory response. It is known that TGF-13 is an extremely potent chemoattractant for macrophages (49) .
Thus, it is conceivable that TGF-,8-induced neovascularization is a consequence of the release of angiogenic products from attracted macrophages. It remains to be seen whether a similar mechanism could be responsible for the angiogenic activity of TNF-a. Proc. Natl. Actad. Sci. USA 84 (1987) 
